Thus, preventing MLCK1 recruitment to the perijunctional actomyosin ring may be a non-toxic approach to limiting or preventing immune-mediated colitis either alone or in combination with immunomodulatory agents, e.g., anti-TNF [128] (Figure 4). Here, TNF is linked to colitis.